MOdel-informed precision dosing (MIPD) of ustekinumab and VEdolizumab in inflammatory bowel disease: protocol for an Independent randomised, controlled, multicentre Trial (MOVE-IT).

Saved in:
Bibliographic Details
Title: MOdel-informed precision dosing (MIPD) of ustekinumab and VEdolizumab in inflammatory bowel disease: protocol for an Independent randomised, controlled, multicentre Trial (MOVE-IT).
Authors: Frimor C; Department of Medical Gastrointestinal Diseases, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark Faculty of Health Sciences, Odense, Denmark., Steenholdt C; Department of Medical Gastrointestinal Diseases, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark Faculty of Health Sciences, Odense, Denmark., Widigson ESK; Department of Clinical Pharmacy and Biochemistry, Freie Universität Berlin Institut für Pharmazie, Berlin, Germany.; Graduate Research Training Program PharMetrX (Pharmacometrics and Computational Disease Modelling), Freie Universität Berlin, Berlin, Germany., Kjeldsen J; Department of Medical Gastrointestinal Diseases, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark Faculty of Health Sciences, Odense, Denmark., Larsen L; Department of Gastroenterology and Hepatology, Aalborg Universitetshospital, Aalborg, Denmark.; Center of Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Aalborg Universitet, Copenhagen, Denmark., Burisch J; Gastro Unit Medical Division, Hvidovre Hospital Gastro Unit, Hvidovre, Denmark.; Department of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark., Joergensen MT; Department of Internal Medicine, Vejle Hospital, Vejle, Region Syddanmark, Denmark.; Department of Clinical Medicine, University of Southern Denmark Faculty of Health Sciences, Odense, Denmark., Halling ML; Department of Internal Medicine, Esbjerg Central Hospital, Esbjerg, Denmark., Kloft C; Department of Clinical Pharmacy and Biochemistry, Freie Universität Berlin Institut für Pharmazie, Berlin, Germany., Ainsworth MA; Department of Medical Gastrointestinal Diseases, Odense University Hospital, Odense, Denmark mark.ainsworth@rsyd.dk.; Department of Clinical Research, University of Southern Denmark Faculty of Health Sciences, Odense, Denmark.
Source: BMJ open gastroenterology [BMJ Open Gastroenterol] 2025 Dec 25; Vol. 12 (1). Date of Electronic Publication: 2025 Dec 25.
Publication Type: Journal Article; Clinical Trial Protocol
Journal Info: Publisher: BMJ Publishing Group Ltd & British Society of Gastroenterology Country of Publication: England NLM ID: 101660690 Publication Model: Electronic Cited Medium: Print ISSN: 2054-4774 (Print) Linking ISSN: 20544774 NLM ISO Abbreviation: BMJ Open Gastroenterol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2054-4774
DOI:10.1136/bmjgast-2025-001985